Abstract:Brucellosis, caused by Brucella spp., is one of the most widespread bacterial zoonoses worldwide. Vaccination is still considered the best way to control brucellosis. An investigation into the differential proteome expression patterns of wild and vaccine strains may help researchers and clinicians differentiate between the strains to diagnose and better understand the mechanism(s) underlying differences in virulence. In the present study, a mass spectrometry-based, label-free relative quantitative proteomics approach was used to investigate the proteins expressed by the wild strain, B. melitensis biovar 3 and compare it with those expressed by B. melitensis M5-90. The higher level of virulence for B. melitensis biovar 3 compared to B. melitensis M5-90 was validated in vitro and in vivo. A total of 2133 proteins, encompassing 68% of the theoretical proteome, were identified and quantified by proteomic analysis, resulting in broad coverage of the B. melitensis proteome. A total of 147 proteins were identified as differentially expressed (DE) between these two strains. In addition, 9 proteins and 30 proteins were identified as unique to B. melitensis M5-90 and B. melitensis biovar 3, respectively. Pathway analysis revealed that the majority of the DE proteins were involved in iron uptake, quorum sensing, pyrimidine metabolism, glycine betaine biosynthetic and metabolic processes, thiamine-containing compound metabolism and ABC transporters. The expression of BtpA and VjbR proteins (two well-known virulence factors) in B. melitensis biovar 3 was 8-fold and 2-fold higher than in B. melitensis M5-90. In summary, our results identified many unique proteins that could be selected as candidate markers for differentiating vaccinated animals from animals with wild-type infections. BtpA and VjbR proteins might be responsible for the residual virulence of B. melitensis M5-90, while ABC transporters and thiamine metabolism associated proteins may be newly identified Brucella virulence factors. All of the identified DE proteins provide valuable information for the development of vaccines and the discovery of novel therapeutic targets.

Altered Transcriptome Of The B-Melitensis Vaccine Candidate 16m Delta Vjbr, Implications For Development Of Genetically Marked Live Vaccine

Altered Transcriptome of the B. melitensis Vaccine Candidate 16MΔvjbR, Implications for Development of Genetically Marked Live Vaccine

The 16m Delta Vjbr As An Ideal Live Attenuated Vaccine Candidate For Differentiation Between Brucella Vaccination And Infection

The 16MΔvjbR as an ideal live attenuated vaccine candidate for differentiation between Brucella vaccination and infection.

Attenuation Mechanism of Brucella Melitensis M5-10, Implications for Vaccine Development and Differential Diagnosis

Using a Relative Quantitative Proteomic Method to Identify Differentially Abundant Proteins in Brucella melitensis Biovar 3 and Brucella melitensis M5-90

Evaluation and Differential Diagnosis of a Genetic Marked Brucella Vaccine A19ΔvirB12 for Cattle

Brucella melitensis 16MΔTcfSR as a potential live vaccine allows for the differentiation between natural and vaccinated infection.

Comparative proteome analysis of Brucella melitensis vaccine strain Rev 1 and a virulent strain, 16M

Study on the Biological Characteristics of Vaccine Candidate RB6 Derived from Brucella abortus

Comparative Proteomics Analyses Reveal the Virb of B. Melitensis Affects Expression of Intracellular Survival Related Proteins.

Transcriptome Analysis of Gene Expression Profiling of Infected Macrophages Between Brucella Suis 1330 and Live Attenuated Vaccine Strain S2 Displays Mechanistic Implication for Regulation of Virulence.

Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine

The Brucella Melitensis M5-90ΔmanB Live Vaccine Candidate is Safer Than M5-90 and Confers Protection Against Wild-Type Challenge in BALB/c Mice.

Biological characteristics of vaccine candidate A19-ΔVirB12 mutant strain of Brucella abortus

Brucella melitensis 16MΔhfq attenuation confers protection against wild-type challenge in BALB/c mice.

Brucella Melitensis M5-90Δbp26 As a Potential Live Vaccine That Allows for the Distinction Between Natural Infection and Immunization.

Parenteral Vaccination with a Live Brucella melitensis Mutant Protects against Wild-Type B. melitensis 16M Challenge

Characterization of Brucella Abortus Mutant Strain Δ22915, a Potential Vaccine Candidate

Identification of Brucella abortus virulence proteins that modulate the host immune response

Several Membrane and Cytoplasmic Proteins May be Associated with Virulence Reduction of Brucella Melitensis Strain RM57